Malaria vaccine ‘R21/Matrix-M

Current Context : Serum Institute begins shipments of Malaria Vaccine ‘R21/Matrix-M’ To Africa as part of the global fight against the disease.

• The first shipment is being sent to the Central African Republic (CAR) followed by other African countries such as South Sudan and Democratic Republic of Congo in the coming days
• It is developed in collaboration with the University of Oxford and Novavax’s Matrix-M.
• R21/Matrix-M vaccine is the second malaria vaccine received a recommendation by the World Health Organisation (WHO) for use in children in malaria-endemic regions on October 2023.
• It took 30 years of research at the University of Oxford’s Jenner Institute to develop the R21/Matrix-M vaccine.